NPC1L1 Knockout Huh-7 Cell Line

The choice depends on whether you are studying NPC1L1 (Niemann-Pick C1-like 1)'s role as the principal intestinal cholesterol uptake transporter or modeling its role in biliary cholesterol reabsorption. The Knockout line is the standard tool for asking whether NPC1L1 is required for cellular cholesterol uptake — NPC1L1 is the direct target of ezetimibe (Zetia), one of the most prescribed cholesterol-lowering drugs. NPC1L1 is principally expressed in intestinal enterocytes (apical) and hepatocyte canalicular membrane, mediating cholesterol absorption from intestine and biliary reabsorption from bile. Overexpression is useful for studying NPC1L1 in heterologous expression contexts. For cholesterol absorption research, the EDITGENE NPC1L1 Knockout in Huh-7 is highly relevant — Huh-7 has hepatocellular origin matching NPC1L1's biliary canalicular expression context. Rescue with wild-type or transport-deficient NPC1L1 is the standard specificity control. The knockout is a critical specificity tool for ezetimibe — ezetimibe specifically inhibits NPC1L1, and the knockout serves as the gold-standard negative control for confirming on-target ezetimibe pharmacology. Cardiovascular outcome studies (IMPROVE-IT) validated NPC1L1 as a cardiovascular protective target through ezetimibe-mediated LDL lowering.

Primary applications: • Cellular cholesterol uptake: cholesterol uptake assays using fluorescent cholesterol analogs (NBD-cholesterol, BODIPY-cholesterol) or radiolabeled cholesterol. • Ezetimibe specificity: critical genetic control for ezetimibe — ezetimibe should have no effect in NPC1L1-null cells; rescue with wild-type NPC1L1 restores ezetimibe sensitivity. • Biliary cholesterol biology: hepatic cholesterol secretion and biliary cholesterol composition studies in Huh-7 hepatocellular context. • Cardiovascular protection: studies linking NPC1L1-mediated cholesterol absorption to LDL levels and cardiovascular outcomes (IMPROVE-IT trial validation). EDITGENE recommends this model for researchers investigating intestinal/biliary cholesterol absorption, ezetimibe pharmacology, and cardiovascular drug development.

Yes. NPC1L1 rescue experiments are well-established for cholesterol absorption research: • Construct design: use a codon-modified NPC1L1 sequence with a small intracellular C-terminal tag (FLAG, HA). NPC1L1 has 13 transmembrane domains with a sterol-sensing domain (SSD) — preserve membrane topology. • Transport-deficient rescue: SSD or sterol-binding pocket mutations abolish cholesterol uptake and serve as the standard specificity control. • Surface localization validation: confirm plasma membrane localization by cell surface staining before functional assays. • Functional readout: rescue should restore cellular cholesterol uptake and ezetimibe sensitivity — these are the two complementary functional readouts for NPC1L1 rescue. Huh-7 transduces efficiently with lentivirus and supports stable rescue line generation in a hepatocellular context relevant to biliary cholesterol biology.